Nivolumab: all 1,111 studies that test it

Page 1 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• A Study of Treatment Delivery Preference In People With Kidney CancerRecruitingNCT07872553Phase 4
• Neoadjuvant RP2 + Nivolumab in Patients With MelanomaNot yet recruitingNCT07862530Phase 2
• Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingNCT07838974Phase 1
• bNAbs and Anti-PD-1 in HIVNot yet recruitingNCT07820813Phase 2
• Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingNCT07770100Phase 2
• Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMDRecruitingNCT07694986Phase 2
• Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaRecruitingNCT07689175Phase 2
• Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma PatientsNot yet recruitingNCT07679841Phase 1/2
• NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain TumorsRecruitingNCT07664176Phase 1
• Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)RecruitingNCT07653503Phase 1
• Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerNot yet recruitingNCT07645118Phase 2
• Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaRecruitingNCT07631325Phase 1/2
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNot yet recruitingNCT07576725Phase 2
• Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingNCT07572123Phase 2/3
• Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLRecruitingNCT07551583Phase 2
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasRecruitingNCT07546812Phase 2
• Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR CancersEnrolling by invitationNCT07542262Phase 2
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingNCT07527858Phase 2
• Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell CarcinomaNot yet recruitingNCT07514767Phase 2
• VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07510334Phase 2
• Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaRecruitingNCT07501117Phase 1
• Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCCNot yet recruitingNCT07494435Phase 2
• Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaRecruitingNCT07476326Phase 1
• Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07460765Phase 1
• A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingNCT07459543Phase 4
• A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingNCT07444619Phase 1
• A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingNCT07430202Phase 1
• Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingNCT07420439Phase 2
• 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsRecruitingNCT07404332Phase 1
• A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsRecruitingNCT07376707Phase 1
• First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingNCT07355205Phase 1/2
• The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Not yet recruitingNCT07338981Phase 3
• Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCRecruitingNCT07246863Phase 2
• Neo-adjuvant Immunotherapy in Patients With Localized MelanomaRecruitingNCT07230613Phase 2
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingNCT07226856Phase 2
• Patient Preference for Subcutaneous vs. Intravenous Immune TherapyRecruitingNCT07223424Phase 2
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingNCT07221149Phase 2/3
• Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingNCT07219459Phase 2
• Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)RecruitingNCT07210632Early Phase 1
• PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaRecruitingNCT07209059Phase 2
• Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesRecruitingNCT07174453Phase 3
• Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialRecruitingNCT07155317Phase 2
• Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell CarcinomaRecruitingNCT07152678Phase 2
• Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of NivolumabRecruitingNCT07100704Phase 2
• Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung CancerRecruitingNCT07084610Phase 2
• Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCRecruitingNCT07050043Phase 3
• A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.RecruitingNCT07017816Early Phase 1
• Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingNCT07013565Phase 2
• Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)RecruitingNCT06999980Phase 2
• Nivo40-AVD for Advanced Classic Hodgkin LymphomaRecruitingNCT06984146Phase 2
• Saci Nivo Rela for TNBCRecruitingNCT06963905Phase 1/2
• A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal CancerRecruitingNCT06948448Phase 2
• ONO-4538 Study in Patients With Richter's TransformationRecruitingNCT06936943Phase 2
• Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingNCT06934057Phase 4
• Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab TreatmentEnrolling by invitationNCT06931613Phase 2
• Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingNCT06926790Phase 2
• Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaEnrolling by invitationNCT06896110Phase 1
• SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 1
• Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell LymphomaEnrolling by invitationNCT06871007Phase 1/2
• Towards Cure Via Only Ultra-short ICB in CSCCRecruitingNCT06823479Phase 2
• PD-1 Inhibitors Maintenance for cHL Post-autoHCTRecruitingNCT06812858Phase 2
• A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung CancerRecruitingNCT06800339Phase 1
• SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaRecruitingNCT06794775Phase 3
• Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisRecruitingNCT06794229Phase 2
• Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaRecruitingNCT06745076Phase 2
• Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyRecruitingNCT06731270Phase 2
• Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingNCT06712927Phase 2
• MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingNCT06712875Phase 1/2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingNCT06683755Phase 1/2
• Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceRecruitingNCT06682728Phase 2
• Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaRecruitingNCT06624475Phase 2
• Study to ONO-4538 in Patients With Rhabdoid TumorRecruitingNCT06622941Phase 2
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Phase 3
• Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant LesionsRecruitingNCT06561087Phase 2
• CD8 PET Imaging in Metastatic Solid TumoursRecruitingNCT06534190Phase 2
• Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingNCT06495125Phase 2
• The Sagittarius TrialRecruitingNCT06490536Phase 3
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingNCT06399419Phase 1
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCRecruitingNCT06364917Phase 2
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/2
• Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular EndoscopyNot yet recruitingNCT06304597Phase 1
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingNCT06295159Phase 2
• Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell CarcinomaRecruitingNCT06288191Phase 2
• Repositioning Immunotherapy in VetArans With Lung CancerRecruitingNCT06275360Phase 2
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingNCT06265285Phase 2
• Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT06245356Phase 2
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaRecruitingNCT06240143Phase 1/2
• Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1
• Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingNCT06203600Phase 2/3
• Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaRecruitingNCT06151236Phase 2
• Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable ResponseRecruitingNCT06116461Phase 4
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingNCT06064097Phase 2
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaRecruitingNCT06053658Phase 2
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
• Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerRecruitingNCT06008925Phase 1/2
• Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell CarcinomaRecruitingNCT05964101Phase 2
• Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesRecruitingNCT05909618Phase 2
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2

← Nivolumab overview